Survival estimates of a prognostic classification depended more on year of treatment than on imputation of missing values

Journal of Clinical Epidemiology

Volumn 59, Issue 3, 2006, Pages 246-253

  Van Dijk, Merel R ^a   Steyerberg, Ewout W ^a   Stenning, Sally P ^b   Habbema, J Dik F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Germ cell cancer; Missing data; Multiple imputation; Prognostic groups

Indexed keywords

ARTICLE; CANCER SURVIVAL; CLASSIFICATION; GERM CELL TUMOR; HUMAN; MEDICAL RECORD; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TESTIS CANCER;

CLASSIFICATION; DATA COLLECTION; DISEASE-FREE SURVIVAL; HUMANS; INFORMATION STORAGE AND RETRIEVAL; LONGITUDINAL STUDIES; MALE; MEDICAL RECORDS; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 32644446010     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2005.08.015     Document Type: Article

References (25)

1. G.J. Bosl, and R.J. Motzer Testicular germ-cell cancer N Engl J Med 337 1997 242 253 [Erratum in: N Engl J Med 1997;337:1403]
2. J.T. Hartmann, L. Kanz, and C. Bokemeyer Diagnosis and treatment of patients with testicular germ cell cancer Drugs 58 1999 257 281
3. G.S. Steele, J.P. Richie, A.K. Stewart, and H.R. Menck The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996 Cancer 86 1999 2171 2183
4. D.J. Sonneveld, H.J. Hoekstra, W.T. van der Graaf, W.J. Sluiter, N.H. Mulder, P.H. Willemse, H.S. Koops, and D.T. Sleijfer Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era Cancer 91 2001 1304 1315
5. International Germ Cell Cancer Collaborative Group (IGCCCG) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers J Clin Oncol 15 1997 594 603
6. M.R. van Dijk, E.W. Steyerberg, S.P. Stenning, E. Dusseldorp, and J.D. Habbema Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning Br J Cancer 90 2004 1176 1183
7. S. van Buuren, H.C. Boshuizen, and D.L. Knook Multiple imputation of missing blood pressure covariates in survival analysis Stat Med 18 1999 681 694
8. D.B. Rubin, and N. Schenker Multiple imputation in health-care databases: an overview and some applications Stat Med 10 1991 585 598
9. J.L. Schafer Multiple imputation: a primer Stat Methods Med Res 8 1999 3 15
10. J.A. McCaffrey, D.F. Bajorin, and R.J. Motzer Risk assessment for metastatic testis cancer Urol Clin North Am 25 1998 389 395
11. A. Briggs, T. Clark, J. Wolstenholme, and P. Clarke Missing... presumed at random: cost-analysis of incomplete data Health Econ 12 2003 377 392
12. A. Perez, R.J. Dennis, J.F. Gil, M.A. Rondon, and A. Lopez Use of the mean, hot deck and multiple imputation techniques to predict outcome in intensive care unit patients in Colombia Stat Med 21 2002 3885 3896
13. T.G. Clark, and D.G. Altman Developing a prognostic model in the presence of missing data: an ovarian cancer case study J Clin Epidemiol 56 2003 28 37
14. D.B. Rubin Multiple imputation for nonresponse in surveys 1987 Wiley New York
15. R.J.A. Little, and D.B. Rubin Statistical analysis with missing data 2nd edition 2002 John Wiley and Sons New York
16. W.R. Gilks S. Richardson D.J. Spiegelhalter Markov chain Monte Carlo in practice 1996 Chapman & Hall London
17. F.E. Harrell Jr., K.L. Lee, R.M. Califf, D.B. Pryor, and R.A. Rosati Regression modelling strategies for improved prognostic prediction Stat Med 3 1984 143 152
18. F.E. Harrell Jr., K.L. Lee, D.B. Matchar, and T.A. Reichert Regression models for prognostic prediction: advantages, problems, and suggested solutions Cancer Treat Rep 69 1985 1071 1077
19. J.R. Germa-Lluch, X. Garcia del Muro, J.M. Tabernero, M. Sanchez, J. Aparicio, E. Alba, and A. Barnadas BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: The Spanish Germ-Cell Cancer Group experience (GG) Ann Oncol 10 1999 289 293
20. M.P. Decatris, P.M. Wilkinson, R.S. Welch, M. Metzner, G.R. Morgenstern, and M. Dougall High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity Ann Oncol 11 2000 427 434
21. G. Tscherry, E. Jacky, L.M. Jost, and R.A. Stahel Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients: a single-center study Oncology 59 2000 110 117
22. C. Bokemeyer, N. Schleucher, B. Metzner, M. Thomas, O. Rick, H.J. Schmoll, C. Kollmannsberger, I. Boehlke, L. Kanz, and J.T. Hartmann First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial Br J Cancer 89 2003 29 35
23. D.A. Anthoney, M.J. McKean, J.T. Roberts, A.W. Hutcheon, J. Graham, W. Jones, J. Paul, and S.B. Kaye Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours Br J Cancer 90 2004 601 606
24. D.J.A. Sonneveld, H.J. Hoekstra, W.T. van der Graaf, W.J. Sluiter, N.H. Mulder, P.H.B. Willemse, H.S. Koops, and D.T. Sleijfer Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era Cancer 91 2001 1304 1315
25. J.R. Germa-Lluch, X. Garcia del Muro, P. Maroto, L. Paz-Ares, J.A. Arranz, J. Guma, E. Alba, J. Sastre, J. Aparicio, A. Fernandez, A. Barnadas, J. Terrassa, A. Saenz, D. Almenar, M. Lopez-Brea, M.A. Climent, M.A. Sanchez, R. Lasso de la Vega, G. Berenguer, X. Perez, and Spanish Germ-Cell Cancer Group (GG) Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG) Eur Urol 42 2002 553 562 discussion 562-3